Statin suppresses sirtuin 6 through miR-495, increasing FoxO1-dependent hepatic gluconeogenesis
Open Access
- 1 January 2020
- journal article
- research article
- Published by Ivyspring International Publisher in Theranostics
- Vol. 10 (25) , 11416-11427
Abstract
Rationale: Statin, the most widely used medication in lowering cholesterol, is also associated with increased risk of type 2 diabetes, but its molecular basis remains unclear.Keywords
This publication has 35 references indexed in Scilit:
- The Deacetylase Sirt6 Activates the Acetyltransferase GCN5 and Suppresses Hepatic GluconeogenesisMolecular Cell, 2012
- The sirtuin SIRT6 regulates lifespan in male miceNature, 2012
- Risk of Incident Diabetes With Intensive-Dose Compared With Moderate-Dose Statin TherapyJAMA, 2011
- Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trialsThe Lancet, 2010
- SirT1 knockdown in liver decreases basal hepatic glucose production and increases hepatic insulin responsiveness in diabetic ratsProceedings of the National Academy of Sciences, 2009
- Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysisThe Lancet, 2008
- Brain Cholesterol Synthesis in Mice Is Affected by High Dose of Simvastatin but Not of PravastatinThe Journal of Pharmacology and Experimental Therapeutics, 2006
- The Coactivator p300 Directly Acetylates the Forkhead Transcription Factor Foxo1 and Stimulates Foxo1-Induced TranscriptionMolecular Endocrinology, 2005
- Nutrient control of glucose homeostasis through a complex of PGC-1α and SIRT1Nature, 2005
- Silent information regulator 2 potentiates Foxo1-mediated transcription through its deacetylase activityProceedings of the National Academy of Sciences, 2004